title: Comparison of in vitro activity of ertapenem with other carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli and Kleibsella species isolated in a tertiary children's hospital.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the susceptibility of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae clinical isolates to ertapenem in a tertiary pediatric care center in Turkey.
  
  
  METHODS
  All isolates of ESBL-producing Enterobacteriaceae were collected from clinical specimens from children, and susceptibility tests were done using the Vitek 2 compact system.
  
  
  RESULTS
  Ninety-nine per cent of the ESBL-producing Escherichia coli isolates were found to be susceptible to ertapenem, 99.5% to imipenem and 100% to meropenem. In the Klebsiella species, 91.5% of the isolates were susceptible to ertapenem, 99.3% to imipenem and 100% to meropenem.
  
  
  CONCLUSIONS
  The results of our data, including isolates from children, showed that ertapenem had high in vitro activity against the majority of the ESBL-producing E. coli and Klebsiella species, as reported in previously published studies. However, additional clinical studies are required to assess the clinical activity of ertapenem and the clinical importance of the resistant isolates.
authors.affiliation: Dr Behcet Uz Children's Training and Research Hospital, Department of Pediatric Infectious Diseases, Republic of Turkey Ministry of Health, Izmir, Turkey. ilkerdevrim2003@yahoo.com
authors.forename: Ilker
authors.initials: I
authors.lastname: Devrim
authors.forename: Gamze
authors.initials: G
authors.lastname: Gulfidan
authors.forename: Ilker
authors.initials: I
authors.lastname: Gunay
authors.forename: Hasan
authors.initials: H
authors.lastname: Agın
authors.forename: Barış
authors.initials: B
authors.lastname: Güven
authors.forename: Murat Muhtar
authors.initials: MM
authors.lastname: Yılmazer
authors.forename: Ceyhun
authors.initials: C
authors.lastname: Dizdarer
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D006785:Hospitals, University; D006801:Humans; D007709:Klebsiella / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000096:biosynthesis; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams; D001618:beta-Lactamases; D000077727:Ertapenem